Embecta Corp. EMBC Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

ICU MedicalICUI

——

Other financials

Income statement

See full

Revenue$221.8M-14.4%

Gross profit$127.8M-22.1%

Operating income$35.0M-44.4%

Net income-$4.1M-117%

EPS (diluted)-$0.07-118%

Balance sheet

See full

Cash & equivalents$193.4M-8.9%

Total debt$1.4B-12.5%

Total equity-$626.1M+15.0%

Total assets$1.0B-8.1%

Cash flow

See full

Operating cash flow$31.1M-2.2%

CapEx$500.0K+400%

Free cash flow$30.6M-3.5%

Valuation

See full

Market cap$193.41M-64.3%

Enterprise value$1.37B-24.8%

P/E1.7×-4.8×

P/S0.2×-0.3×

Profitability

See full

Gross margin61.9%-1.6pp

Operating margin25.8%+9.7pp

Net margin10.7%+5.8pp

FCF margin19.6%+16.0pp

Returns & leverage

See full

Return on equity71.9%—

Debt / equity0×—

Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Embecta Corp.'s debt instrument, unamortized discount (premium) and debt issuance costs, net?: Embecta Corp. (EMBC) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $15.4M in Q1 2026.
How has Embecta Corp.'s debt instrument, unamortized discount (premium) and debt issuance costs, net changed year-over-year?: Embecta Corp.'s debt instrument, unamortized discount (premium) and debt issuance costs, net decreased by 32.8% year-over-year, from $22.9M to $15.4M.